EUVIMEDEUVIMED entdecken
Crossref

Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning

Koichi Ashizaki iD, Tetsuo Ishikawa iD, Yuko Nomura iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Koichi Ashizaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nomura Dermatology Clinic, Yokohama, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Erythema, Machine Learning. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI, Japan Agency for Medical Research and Development (AMED), Grant for Encouragement of Clinical Research on Atopic Dermatitis, Presentation Award at the 121st Annual Meeting of the Japanese Dermatological Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Persistent facial erythema represents a significant complication in atopic dermatitis (AD) patients undergoing treatment with dupilumab. Stratifying patients based on the erythema course is crucial for elucidating heterogeneous phenotypes and facilitating advanced drug efficacy predictions.

Objectives

This study aimed to identify factors associated with facial erythema severity in dupilumab‐treated AD patients and to establish a prediction model for drug response based on the identified factors.

Methods

Data from a retrospective study conducted between July 2018 and July 2021 were collected and analysed. Patients were categorized into three groups via hierarchical clustering based on the course of facial erythema: early remission, low remission and persistent residual. LightGBM, a supervised gradient boosting decision tree algorithm, was employed to discern group differences and construct a prediction model. The model incorporated patient demographic and clinical profiles, including pre‐ and post‐treatment examinations. The model's performance was evaluated using accuracy and the area under the receiver operating characteristic curve (AUC).

Results

The binary classification model demonstrated an accuracy of 89.10% and an AUC of 0.862 when distinguishing between early remission and persistent residual patients. The eight prominent factors associated with facial erythema severity included age, sex, lactate dehydrogenase (LDH), immunoglobulin E (IgE), eosinophil count, white blood cell count, Alnus allergy and cedar allergy.

Conclusions

This study has two main significances: first, three clusters were identified through unsupervised learning; second, a classification model was constructed that proved more accurate than random prediction. The stratification and identification of crucial factors associated with residual facial erythema in dupilumab‐treated AD patients lay the foundation for AI‐powered prognostic models. This groundwork provides a substantial basis for enhancing future medical AI support in AD treatment selection, potentially improving personalized treatment approaches and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedErythemaMachine LearningHumansFemaleMaleRetrospective StudiesAdultMiddle AgedFacial DermatosesSeverity of Illness IndexFaceYoung AdultL-Lactate DehydrogenaseLeukocyte Count

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Nomura Dermatology Clinic, Yokohama, Japan.
  • Advanced Data Science Project, RIKEN Information R&D and Strategy Headquarters, RIKEN, Yokohama, Japan.
  • Collective Intelligence Research Laboratory, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan.
  • Department of Extended Intelligence for Medicine, The Ishii-Ishibashi Laboratory, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Koichi Ashizaki, Tetsuo Ishikawa, Yuko Nomura

Förderung

  • Japan Society for the Promotion of Science (JSPS) KAKENHI
  • Japan Agency for Medical Research and Development (AMED)
  • Grant for Encouragement of Clinical Research on Atopic Dermatitis, Presentation Award at the 121st Annual Meeting of the Japanese Dermatological Association
  • Japan Society for the Promotion of Science

Zitieren

APA

Ashizaki, K., Ishikawa, T., & Nomura, Y. (2024). Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19909

Vancouver

Ashizaki K, Ishikawa T, Nomura Y. Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19909

BibTeX
@article{Ashizaki2024,
  author = {Ashizaki, Koichi and Ishikawa, Tetsuo and Nomura, Yuko},
  title = {Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19909}
}
Kostenlos starten →